# Sabah Oney

> Sabah Oney is the president and CEO of Dispatch Bio, a Philadelphia- and San Francisco-based biotech engineering a universal treatment for solid tumors using CAR-T cell therapy. Born in Cyprus and in the U.S. since age 18, he holds a genetics degree from the University of Kansas, a PhD in genetics and genomics from Duke, and an MBA from Stanford. Across nearly two decades in biotech he helped scale Ariosa Diagnostics (acquired by Roche), took Alector public as its chief business officer, co-founded Vilya, and served as a venture partner at ARCH. Dispatch launched publicly in 2025 with $216 million behind its FLARE platform and CAR-T pioneer Carl June among its founders.

- **Role:** President and CEO at Dispatch Bio
- **Organizations:** Dispatch Bio, ARCH Venture Partners, Vilya, Alector, Ariosa Diagnostics, Fred Hutchinson Cancer Center
- **From:** Cyprus
- **Nationality:** Cypriot-American
- **Education:** B.S. in Genetics, The University of Kansas, PhD in Genetics and Genomics, Duke University, MBA (finance and strategy), Stanford Graduate School of Business
- **Known for:** Leads Dispatch Bio, which raised $216 million led by ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy, Helped take Alector public as Chief Business Officer and executive committee member, Oversaw the global expansion of Ariosa Diagnostics, acquired by Roche in 2015

## Career timeline

- **2012** — Earned MBA from Stanford GSB; joined Ariosa Diagnostics, overseeing global expansion of its non-invasive prenatal genetic testing
- **2015** — Ariosa Diagnostics acquired by Roche
- **2016-2021** — Chief Business Officer of Alector; member of the Executive Committee; guided the company through its IPO and major partnerships
- **2021** — Joined ARCH Venture Partners as a Venture Partner
- **2022** — Co-founded and served as interim CEO of Vilya, a computational biotech launched by Nobel laureate David Baker; trekked to Everest Base Camp for the Climb to Fight Cancer, raising nearly $97,000
- **2025** — Dispatch Bio launched publicly with $216M in funding and Sabah Oney as President and CEO
- **2026** — Joined the Fred Hutch Cancer Center Board of Directors, effective January 1, 2026

## Achievements

- Leads Dispatch Bio, which raised $216 million led by ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy
- Helped take Alector public as Chief Business Officer and executive committee member
- Oversaw the global expansion of Ariosa Diagnostics, acquired by Roche in 2015
- Co-founded Vilya with Nobel laureate David Baker
- Raised nearly $97,000 for cancer research on the 2022 Climb to Fight Cancer trek to Everest Base Camp
- Named to the Fred Hutch Cancer Center Board of Directors in 2026
- Co-author of numerous scientific publications and inventor on several biotechnology patents

## Latest updates

- **2026-01** — Joined the Fred Hutch Cancer Center Board of Directors, effective January 1, 2026
- **2025-08** — Featured on Timmerman Report's 'The Long Run' podcast discussing CAR-T against solid tumors
- **2025-07** — Dispatch Bio launched publicly with $216M total funding; first program expected to enter clinical trials in 2026

## Links

- Website: https://dispatchbio.com
- LinkedIn: https://www.linkedin.com/in/sabahoney/
- Twitter/X: https://x.com/sabahoney

---

Profile page: https://yespress.io/sabah-oney
Published by YesPress — https://yespress.io
Last updated: 2026-07-29